Movement Disorders

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network. for the week ending June 29, 2024. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on epilepsy/Dravet syndrome.

Overall, the treatment resulted in dose-dependent trends of improvement on key clinical measures including Total Functional Capacity and Composite Unified Hungtinton's Disease Rating Scale.

The Cleveland Clinic Foundation Parkinson's Inpatient Program is a proactive, multidisciplinary intervention aimed to enhance the quality and safety of care for hospitalized patients with Parkinson disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 28, 2024.

Istradefylline led to significant reductions in tremor and motor symptoms in patients with Parkinson disease over 24 weeks.

Findings revealed that 27% of patients responded to the treatment of continuous subcutaneous apomorphine infusion and sustained efficacy overtime in patients with Parkinson disease.

The movement disorder specialist at Texas Movement Disorder Specialists talked about a comprehensive panel discussion that highlighted the evolution of Parkinson disease treatment. [WATCH TIME: 4 minutes]

The nurse practitioner at the Cleveland Clinic talked about a specialized program involving nurse practitioners that aims to improve inpatient care quality and safety for patients with Parkinson disease. [WATCH TIME: 5 minutes]

Bezisterim has shown potential in improving non-motor symptoms like fatigue and sleep issues, with promising results from previous studies.

Modified Functional Status Questionnaire, an assessment of activities of daily living, includes several different notable domains, including quality of interaction, social activity, and psychological function.

In the CRL, the agency cited observations identified during inspection of a third-party manufacturer listed in the NDA. If approved, ABBV-951 would be the first subcutaneous delivery option of carbidopa/levodopa.

The director of the Memory Disorders Program at Georgetown University talked about newly approved anti-amyloid antibodies that show significant promise in slowing Alzheimer disease progression. [WATCH TIME: 5 minutes]

Although the data used predated 2019, istradefylline was associated with a statistically significant lower odds of the overall incidence of treatment-emergent adverse events than other adjunctive therapies for Parkinson disease.

StrivePD and Apple Watch continuously track motor symptoms, aiding neurologists in adjusting treatments for better patient outcomes.

In a large-scale analysis. 70% of patients with essential tremor and 70% of undiagnosed patients reported dissatisfaction with the therapeutic options available to treat their condition.

The associate professor of neurology at Georgetown University Medical Center talked about disease-modifying therapies for movement disorder-related dementia that aim to address the underlying mechanisms of the disease. [WATCH TIME: 5 minutes]

The executive director of the Association of Movement Disorder Advanced Practice Providers talked about the need for improved communication and trust of the patient-provider relationship in the field of movement disorders. [WATCH TIME: 3 minutes]

The assistant clinical professor of medicine at Medstar Georgetown University Hospital talked about her presentation at ATMRD where she covered various advanced therapies for managing Parkinson disease and essential tremor. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Approximately 83% of patients reported that they did not disclose to their provider that they experienced symptoms or had concerns about living with a movement disorder.

The director of movement disorders at the Banner Sun Health Research Institute talked about that although synuclein biomarkers have shown high sensitivity in identifying Parkinson disease, further studies are needed to address their limitations. [WATCH TIME: 3 minutes]

In recent analysis indicated that initiating apomorphine hydrochloride injection without antiemetic premedication was well-tolerated among patients with Parkinson disease.

Neurology News Network. for the week ending June 22, 2024. [WATCH TIME: 4 minutes]